MARINOL (dronabinol capsules, USP) is indicated for the treatment of:
1. anorexia associated with weight loss in patients with AIDS; and
2. nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments.
Important Safety Information1
Contraindications: MARINOL is contraindicated in any patient who has a known sensitivity to MARINOL or any of its ingredients, including cannabinoid and sesame oil.
Warnings: Patients receiving treatment with MARINOL should be specifically warned not to drive, operate machinery, or engage in any hazardous activity until it is established that they are able to tolerate the drug and to perform such tasks safely.
Precautions: The risk/benefit ratio of MARINOL use should be carefully evaluated in patients with the following medical conditions because of individual variation in response and tolerance to the effects of MARINOL.
MARINOL should be used with caution in patients:
Adverse Reactions: Reported in clinical trials ≥1% were amnesia, anxiety/nervousness, ataxia, confusion, depersonalization, dizziness, euphoria, hallucination, paranoid reaction, somnolence, abnormal thinking, asthenia, palpitations, tachycardia, vasodilation/facial flush, abdominal pain, nausea, and vomiting.